Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
Enrolment site for the investigational UK trials of the Moderna mRNA-1273.529 Omicron-tweaked jab
A clinical trial of a COVID-19 booster vaccine for volunteers ages 16 and older
https://connect.trialscope.com/studies/7dff1448-9e85-4beb-81a4-ec4f9170c769
A clinical trial conducted by Moderna is evaluating an investigational booster vaccine that may protect against the COVID-19 Omicron variant.
Trial ID: mRNA-1273-P305 [EudraCT ID: 2022-000063-51]
https://connect.trialscope.com/studies/7dff1448-9e85-4beb-81a4-ec4f9170c769
A clinical trial conducted by Moderna is evaluating an investigational booster vaccine that may protect against the COVID-19 Omicron variant.
Trial ID: mRNA-1273-P305 [EudraCT ID: 2022-000063-51]
Trial Details
The mRNA-1273-P305 clinical trial is evaluating the safety and immune response of the investigational mRNA-1273.529 booster vaccine that may protect against the COVID-19 Omicron variant. The investigational mRNA-1273.529 booster is being compared to a booster dose of Moderna’s COVID-19 vaccine, Spikevax, which is the vaccine that received conditional marketing authorization in the EU. All participants will receive either mRNA-1273.529 or Spikevax.
With different strains of COVID-19, there is an urgent need to develop vaccination plans that will provide greater protection. A booster vaccine that protects against COVID-19 variants, including the Omicron variant, would be a crucial public health tool to help curb the pandemic.
Estimated Enrolment - 3000 Participants
Phase 2/3
The mRNA-1273-P305 clinical trial is evaluating the safety and immune response of the investigational mRNA-1273.529 booster vaccine that may protect against the COVID-19 Omicron variant. The investigational mRNA-1273.529 booster is being compared to a booster dose of Moderna’s COVID-19 vaccine, Spikevax, which is the vaccine that received conditional marketing authorization in the EU. All participants will receive either mRNA-1273.529 or Spikevax.
With different strains of COVID-19, there is an urgent need to develop vaccination plans that will provide greater protection. A booster vaccine that protects against COVID-19 variants, including the Omicron variant, would be a crucial public health tool to help curb the pandemic.
Estimated Enrolment - 3000 Participants
Phase 2/3
Eligibility Criteria
Participants must:
Be 16 years of age or older
Be in good health
Have previously received two or three doses of the COVID-19 vaccine
Participants who have previously received a third dose must have received an mRNA vaccine (Moderna, Pfizer/BioNTech) as a third dose
Participants who have previously received two doses may have received mRNA (Moderna, Pfizer/BioNTech) or non-mRNA (Oxford/AstraZeneca, Janssen) vaccines
Participants must not:
Have received a COVID-19 vaccine within the past 3 months
Have tested positive for COVID-19 since November 8, 2021 or have had significant exposure to someone who has tested positive within the past 14 days
Have participated in another trial in the past 28 days
Participants must:
Be 16 years of age or older
Be in good health
Have previously received two or three doses of the COVID-19 vaccine
Participants who have previously received a third dose must have received an mRNA vaccine (Moderna, Pfizer/BioNTech) as a third dose
Participants who have previously received two doses may have received mRNA (Moderna, Pfizer/BioNTech) or non-mRNA (Oxford/AstraZeneca, Janssen) vaccines
Participants must not:
Have received a COVID-19 vaccine within the past 3 months
Have tested positive for COVID-19 since November 8, 2021 or have had significant exposure to someone who has tested positive within the past 14 days
Have participated in another trial in the past 28 days
Check Eligibility
Complete a few questions to check qualifications.
snip
